Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines
David Toung downgraded Bristol-Myers Squibb from Buy to Hold, citing significant risks arising from the Celgene merger.
The primary concern is the loss of exclusivity and patent cliff issue for Celgene's Revlimid, the analyst said.
Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.
Toung said he's not confident about Celgene's pipeline delivering sufficient revenue to offset the eventual decline in Revlimid revenues when it loses its exclusivity in 2026.
Additionally, Bristol-Myers Squibb's Opdivo could come under pressure from Merck & Co., Inc. (NYSE:MRK)'s Keytruda, as the latter establishes its supremacy in the first-line treatment of non-small cell lung cancer, the analyst said.
Competition could also come from other new immuno-oncology drugs, he said.
The combined company will be weighed down by a heavy debt pile of more than $45 billion, restricting the use of cash for R&D, M&A and in-licensing of new assets, according to Argus.
The Price Action
Bristol-Myers Squibb shares were down 1.1 percent at $46.34 at the time of publication Monday, while Celgene shares were down 0.61 percent at $94.84.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.